GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

Shortly after President Donald Trump won his second presidential election in the U.S. last fall, British drugmaker GSK came to federal prosecutors in New York, bearing intel from employees ...

GSK is studying a group of more than a million older adults in the UK to see if its shingles vaccine lowers the risk of dementia. The British drugs group, led by boss Emma Walmsley, is using the ...

GSK said last year the antibiotic succeeded in a late-stage trial and plans to seek approval in that indication as well. GSK scientists discovered the drug, which was developed in part through the ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics for the condition in nearly 30 years. Blujepa, also ...

GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for ...

LONDON, March 25 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles ...

GSK plans U.S. launch in second half of the year GSK expects Blujepa and other drugs to contribute to over £2 billion in peak sales Blujepa's unique action reduces bacterial resistance risk, GSK ...

The research collaboration will probe the incidence rate of dementia in those people and whether or not they received a GSK shingles vaccine. This analysis builds off a bit of happenstance that ...

More than 55 million people worldwide have dementia, according to the WHO. Credit: Alican Lazutti via Getty Images. GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health ...

Learn More. Just over a year ago, I ran the rule over GSK (LSE: GSK) shares. They looked very cheap and were offering a growing dividend. However, I chose instead to invest in FTSE 100 ...